Aspiration pneumonia
ICD-10 J69.0 · ICD-11 CA71.0

Treatment of Aspiration Pneumonia with Bronchiectasis, Severe COPD, or Pseudomonas Risk

This protocol addresses severe aspiration pneumonia — meeting established clinical severity criteria — in patients who carry at least one structural lung condition or microbiological risk factor that substantially alters the expected pathogen spectrum.

Clinical Scenario

Aspiration pneumonia with severity criteria, plus at least one of the following:

Empirical Antibiotic Approach

Empirical intravenous antibiotic therapy with targeted activity against Pseudomonas aeruginosa and MRSA risk is indicated. Dosing is adjusted based on renal function. The complete regimen, drug selection, and dosing intervals are available in the full protocol below.

Clinical Stability Goals — Assessed at 72 Hours
Temp ≤ 37.8 °C SBP ≥ 90 mm Hg HR ≤ 100/min RR ≤ 24/min SpO₂ ≥ 90% or PaO₂ ≥ 60 mm Hg
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.idnow.2025.105081

It is recommended to consider risk factors for infection that could involve Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) (Grade B-1).

Piperacillin-tazobactam is recommended as the empirical treatment for patients with at least one of the following risk factors: documented history of recent respiratory tract colonization or infection (<1 year) due to Pseudomonas, recent parenteral antibiotic therapy (<3 months), severe chronic obstructive pulmonary disease (COPD), bronchiectasis, tracheostomy (Grade B-1).

The positive clinical course is evaluated at 72 h by the presence of all of the following clinical stability criteria: Temperature ≤ 37.8 °C, Systolic blood pressure ≥ 90 mm Hg, Heart rate ≤ 100/min, Respiratory rate ≤ 24/min, SpO2 ≥ 90% or PaO2 ≥ 60 mm Hg in ambient air.

View source ↗